SMT201500124B - Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco - Google Patents

Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco

Info

Publication number
SMT201500124B
SMT201500124B SM201500124T SM201500124T SMT201500124B SM T201500124 B SMT201500124 B SM T201500124B SM 201500124 T SM201500124 T SM 201500124T SM 201500124 T SM201500124 T SM 201500124T SM T201500124 B SMT201500124 B SM T201500124B
Authority
SM
San Marino
Prior art keywords
bisphosphonates
compositions
treatment
methods
heart failure
Prior art date
Application number
SM201500124T
Other languages
English (en)
Inventor
Kenneth W Lyles
Cathleen S Colon-Emeric
Christopher O'connor
Richard S Stack
Niaye Colleen Stack-D
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of SMT201500124B publication Critical patent/SMT201500124B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SM201500124T 2009-09-01 2015-05-26 Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco SMT201500124B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23879709P 2009-09-01 2009-09-01
PCT/US2010/047417 WO2011028737A2 (en) 2009-09-01 2010-09-01 Bisphosphonate compositions and methods for treating heart failure

Publications (1)

Publication Number Publication Date
SMT201500124B true SMT201500124B (it) 2015-07-09

Family

ID=43649931

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500124T SMT201500124B (it) 2009-09-01 2015-05-26 Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco

Country Status (12)

Country Link
US (2) US9867838B2 (it)
EP (1) EP2473172B1 (it)
CN (2) CN105920023A (it)
DK (1) DK2473172T3 (it)
ES (1) ES2537216T3 (it)
HR (1) HRP20150496T1 (it)
HU (1) HUE025737T2 (it)
PL (1) PL2473172T3 (it)
PT (1) PT2473172E (it)
SI (1) SI2473172T1 (it)
SM (1) SMT201500124B (it)
WO (1) WO2011028737A2 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EP2780021A4 (en) * 2011-11-16 2015-08-05 Univ Duke BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2021207047A1 (en) * 2020-04-06 2021-10-14 Duke University Compositions and methods for the treatment of infection-induced cardiomyopathy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3770982D1 (de) 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5057505A (en) 1986-11-21 1991-10-15 Ciba-Geigy Corporation Substituted aminomethanediphosphonic acids and use in medicaments
DE10199052I1 (de) 1986-11-21 2002-01-10 Novartis Ag Neue substituierte Alkandiphosphonsaeuren
GB8808138D0 (en) 1988-04-07 1988-05-11 Leo Pharm Prod Ltd Chemical compounds
ATE120753T1 (de) 1990-08-21 1995-04-15 Upjohn Co Bisphosphonsäurederivate als antiarthritische mittel.
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
HUT66379A (en) 1991-05-28 1994-11-28 Procter & Gamble Calcium, trace mineral, vitamin d and drug therapy combinations
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5403829A (en) 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5646134A (en) 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US6117856A (en) 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
DE19738005A1 (de) * 1997-08-30 1999-03-04 Bayer Ag Verwendung von substituierten 1,1-Bisphosphonaten
EP1051511A1 (en) 1998-01-29 2000-11-15 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
JP2003519183A (ja) 2000-01-04 2003-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
AU2001239953A1 (en) * 2000-03-01 2001-09-12 University Of South Florida Methods of modulating cell-adhesion mediated drug resistance
GB0012209D0 (en) 2000-05-19 2000-07-12 Novartis Ag Organic compounds
KR100864743B1 (ko) 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
JP2004528340A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト ビスホスホネートの医薬的使用
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
WO2003094851A2 (en) 2002-05-11 2003-11-20 Ilex Products, Inc. 1,1- and 1,2-bisphosphonates as apoliprotein e modulators
US20050026871A1 (en) 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
AU2003270196A1 (en) * 2002-09-16 2004-04-30 Kenneth W. Lyles Method for preventing or reducing secondary fractures after hip fracture
CA2502284A1 (en) 2002-10-15 2004-04-29 Novartis Ag Bisphosphonates for the treatment of antheroscleorosis and devices comprising them
EP1587474B1 (en) * 2002-12-30 2009-11-18 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
US20060051407A1 (en) 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
AU2004253527B2 (en) 2003-06-27 2010-04-08 Zuli Holdings Ltd. Method of treating acute coronary syndromes
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
AU2004273672A1 (en) 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
GB0327742D0 (en) * 2003-11-28 2003-12-31 Isis Innovation Novel uses of known drugs
US20060069068A1 (en) 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by pathological calcification
US20060069069A1 (en) * 2004-07-15 2006-03-30 Nanobac Pharmaceuticals, Inc. Methods and compositions for the administration of calcium chelators, bisphosponates and/or citrate compounds and their pharmaceutical uses
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP2007397B1 (en) * 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
EP1925621A1 (en) * 2006-11-27 2008-05-28 Novartis AG Crystalline forms of zoledronic acid
US20080146489A1 (en) 2006-12-15 2008-06-19 Pacetti Stephen D Regional delivery of therapeutic agents for the treatment of vascular diseases
US20100144679A1 (en) 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
CN101259133A (zh) * 2008-03-28 2008-09-10 王洪 唑来磷酸用于制备预防及治疗骨质疏松症的药物
US20110112053A1 (en) 2008-04-16 2011-05-12 University Of Utah Research Foundation Pharmacological targeting of vascular malformations

Also Published As

Publication number Publication date
PL2473172T3 (pl) 2015-08-31
WO2011028737A3 (en) 2011-07-14
US20180125869A1 (en) 2018-05-10
WO2011028737A8 (en) 2012-05-18
CN102639137A (zh) 2012-08-15
HRP20150496T1 (hr) 2015-08-14
EP2473172A2 (en) 2012-07-11
PT2473172E (pt) 2015-06-25
EP2473172A4 (en) 2013-01-16
HUE025737T2 (en) 2016-05-30
EP2473172B1 (en) 2015-04-08
ES2537216T3 (es) 2015-06-03
US20120208786A1 (en) 2012-08-16
SI2473172T1 (sl) 2015-07-31
DK2473172T3 (en) 2015-06-15
CN105920023A (zh) 2016-09-07
US9867838B2 (en) 2018-01-16
WO2011028737A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
IL272817A (en) New preparations and methods for the treatment of vaccine-related diseases
SMT201500124B (it) Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco
EP2129683A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
SMT201700014B (it) Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo
HK1202558A1 (en) Compositions and methods for the therapy and diagnosis of influenza
EP2440209A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
EP2279009A4 (en) METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
SMT201400160B (it) Nuove composizioni per il trattamento di cmt e malattie correlate
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
SMT201600041B (it) Agenti terapeutici 713
IT1403587B1 (it) Composizione per il trattamento di disordini metabolici
BR112013004683A2 (pt) "conjunto de cateter para tratamento de nervo"
ITRM20080546A1 (it) Sedia ginnica per la stimolazione dell'apparato muscolo-scheletrico
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
SMT201600224B (it) Trattamento dell'osteoporosi
SMT201300156B (it) Composti solfonammidici per il trattamento di disturbi respiratori
BR112013007039A2 (pt) "composição de tratamento pessoal"
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
GB0806047D0 (en) Treatment of heart failure
IT1401083B1 (it) Composizione per il trattamento e la prevenzione dell'herpes simplex labiale.
IT1397219B1 (it) Composizione farmaceutica o dietetica per il trattamento dell'atopia